NEW YORK (GenomeWeb News) - Perlegen Sciences said this week that it has licensed certain breast cancer biomarkers from Cambridge Enterprise Limited, the commercial arm of Cambridge University, and plans to commercialize the markers as a diagnostic test.
 
The agreement stems from a large-scale breast cancer study Perlegen, Cambridge, and Cancer Research UK began in 2005 that genotyped more than 50,000 women.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.